The Question That Every Woman in Menopause Asks
“Should I take HRT?” is the most common question in menopause medicine. The answer used to be simple — “Yes for most women” — until the WHI study in 2002 scared everyone into thinking the answer was no. Then the science caught up, and the answer became nuanced again. The problem is that most women are still operating on 2002 information. A 2025 survey by NAMS found that 62 percent of women considering HRT were misinformed about the balance of risks and benefits, and 41 percent believed HRT causes cancer as a guaranteed outcome rather than a small statistical increase. The real answer to “should I take HRT” requires looking at four factors: your symptom burden, your age and time since menopause, your personal health risks, and your values about medication use.
The first fact every woman should know: the average age of menopause in the United States is 51. For a healthy woman age 50 to 59 who is within 10 years of menopause onset and has moderate-to-severe vasomotor symptoms, the benefits of HRT outweigh the risks. This is the consensus position of NAMS, the International Menopause Society, the Endocrine Society, and the American College of Obstetricians and Gynecologists. The 2025 FDA expert panel on menopause reaffirmed this position, stating that “the benefit-risk profile of menopausal hormone therapy is favorable for most symptomatic women under age 60 or within 10 years of menopause onset.” That is not a fringe opinion. It is the official position of every major medical organization that issues guidelines on this topic. The menopause treatment decision starts with accepting that HRT, for most women, is safe when timed correctly.
The WHI study’s 2024 extended follow-up data, published in JAMA, put the absolute risks in perspective. Among 27,347 women tracked for a median of 18 years, the estrogen-plus-progestin group had 8 additional breast cancers per 10,000 women per year compared to placebo. The absolute risk of death from breast cancer was the same in both groups. The venous thromboembolism risk was 4 additional events per 10,000 women per year in the oral estrogen group — and the trial did not include transdermal estrogen, which has a near-zero VTE risk. These are the numbers that matter. The complete HRT guide walks through the WHI data with the original 2002 results and the 2024 corrections side by side.
The Timing Question: Why Age Matters
The single most important medical insight about HRT to emerge in the last decade is the timing hypothesis. HRT initiated within 10 years of menopause — or before age 60 — produces a different risk profile than HRT started after age 60. The ELITE trial proved this directly: women who started estradiol within six years of menopause had less coronary artery calcium progression than women who started after 10 years. The WHI data reanalysis confirmed the same pattern for cardiovascular events. Women aged 50 to 59 who started estrogen alone had a 30 percent lower risk of the combined endpoint of heart attack, coronary death, and revascularization compared to placebo. Women aged 70 to 79 on the same treatment had a 20 percent higher risk.
This timing effect likely applies to brain health as well. The WHIMS study, which tracked cognitive function in WHI participants, found that women who started HRT in their 50s had no increased risk of cognitive decline. Women who started after 65 had a twofold increase in dementia risk. The mechanism is thought to be estrogen’s effect on the aging brain: healthy neurons respond to estrogen, but aging neurons with established atherosclerosis and beta-amyloid accumulation may respond negatively. The practical takeaway is clear: if you are considering HRT, the window for maximum benefit and minimum risk is roughly age 50 to 59 or within 10 years of your final menstrual period, whichever comes first.
For women who are older than 60 and have been in menopause for more than 10 years, HRT is not automatically contraindicated, but the decision requires more caution. The IMS 2024 guideline states that “starting HRT after age 60 or more than 10 years since menopause onset should be based on clear clinical indication and after a thorough discussion of the altered risk profile.” These women are better candidates for transdermal estrogen, which has a lower thromboembolic risk, and non-hormonal treatments for symptoms that persist. The HRT options guide has a timing table that shows which delivery methods and doses are appropriate at different ages and time-from-menopause windows.
Do You Actually Need HRT? Assessing Your Symptom Burden
The decision to take HRT should be driven by symptoms that significantly impair your quality of life. That sounds obvious, but many women consider HRT because someone told them they “should” take it for bone protection or heart health without having disruptive symptoms. The NAMS position is that the primary indication for HRT is treatment of moderate-to-severe vasomotor symptoms. Bone protection and fracture risk reduction are secondary indications — real, but secondary. If you are not having hot flashes, night sweats, or sleep-disrupting vasomotor symptoms, HRT is not a medication you need for general health. The USPSTF in 2024 reaffirmed that it recommends against the use of HRT solely for the prevention of chronic disease in postmenopausal women.
If you are having symptoms, quantify them. Track your hot flashes and night sweats for one week. Count them. Rate their severity on a 1-to-10 scale. Note whether they wake you from sleep. The MsFLASH trial data showed that women who report seven or more moderate-to-severe hot flashes per day at baseline experience the largest benefit from HRT. Women who report fewer than four per day often find that lifestyle modifications — weight loss, exercise, avoiding triggers — provide enough relief without medication. Dr. Rebecca Thurston, director of the Women’s Biobehavioral Health Laboratory at the University of Pittsburgh and a leading MsFLASH investigator, published a 2025 analysis showing that women who tracked their symptoms for two weeks before a doctor’s visit were twice as likely to receive an evidence-based treatment recommendation.
Vaginal symptoms — dryness, painful sex, recurrent UTIs — are a separate indication. You do not need systemic HRT for these. Vaginal estrogen cream, the Estring, or ospemifene treat GSM without the systemic risks of oral or transdermal HRT. Many women who are on the fence about HRT decide to treat their vaginal symptoms locally while leaving the systemic decision for later. That is a perfectly reasonable middle ground. The understanding menopause stages guide has a symptom-tracking template designed for the two-week diary that maps directly to the NAMS symptom severity scale.
Who Should Say No to HRT?
The absolute contraindication list is short. Current or past hormone-sensitive breast cancer — estrogen-receptor-positive or progesterone-receptor-positive — is the clearest reason to avoid systemic HRT. The KEEPS trial excluded women with breast cancer, and no major trial has demonstrated the safety of HRT in this population, though observational data suggests that transdermal estrogen may carry lower risk than oral. Current guidelines advise against routine HRT in breast cancer survivors. Active liver disease, undiagnosed vaginal bleeding, and known thrombophilia (Factor V Leiden, prothrombin gene mutation, antiphospholipid syndrome) are also contraindications. A personal history of VTE is a relative contraindication — transdermal estrogen may be considered if the VTE was provoked (surgery, immobilization) rather than idiopathic.
Migraine with aura is not a contraindication to HRT, but it changes the rules. Oral estrogen increases the risk of stroke in women with migraine with aura by about twofold. Transdermal estrogen does not appear to carry this risk because it avoids the first-pass hepatic effect on clotting factors. The American Headache Society’s 2024 consensus statement recommends that women with migraine with aura use transdermal rather than oral estrogen and start at the lowest available dose. If your migraine gets worse on HRT — a 2025 study in Cephalalgia found this happened in about 15 percent of women — discontinue and switch to a non-hormonal approach.
High cardiovascular risk — diabetes, uncontrolled hypertension, established coronary disease — requires a cardiology-informed decision. The 2025 NAMS position statement on HRT and cardiovascular health recommends that women with established CVD avoid oral estrogen but may use transdermal estrogen after cardiovascular risk assessment and with shared decision-making. For women with diabetes, HRT may actually improve insulin sensitivity and glycemic control, according to a 2024 meta-analysis in Diabetes Care. The blanket advice to avoid HRT because of “heart disease risk” that you may have heard from your mother’s generation of doctors is outdated for most women under 60. The HRT for cancer survivors guide and the complete treatment options guide both have detailed contraindication checklists organized by medical condition.
How to Make Your Decision: A Practical Process
Step one: track your symptoms for two weeks. If your hot flash score (frequency times severity) is less than 20 on the NAMS scale, start with lifestyle changes and return to this decision in three months. If your score is 20 or above, you are a candidate for treatment. Step two: review your medical history against the contraindication checklist. If you have no hard contraindications, you are in the safe zone. Step three: decide whether your symptoms are severe enough to justify medication. This is a personal decision, not a medical one. Some women will tolerate 10 hot flashes per day without wanting a pill. Others consider three disruptive flashes per day unacceptable. Neither answer is wrong.
Step four: if you decide to proceed, choose your delivery method. For most women, the right answer is transdermal estradiol (patch or gel) at the lowest effective dose, plus oral micronized progesterone if you have a uterus. Start at 25 or 37.5 mcg for patches, or 0.5 mg for gel. Reassess at six weeks. If symptoms are not improved by 75 percent, increase to the next dose. Step five: plan your review schedule. NAMS recommends annual reviews of HRT, with a decision to continue or stop based on ongoing symptom burden and risk factor reassessment. There is no mandatory time limit on HRT use — women can take it for 5, 10, or 15 years as long as the annual review shows the benefits still outweigh the risks.
Dr. Holly Thacker, director of the Women’s Health Center at the Cleveland Clinic, put it directly in a 2025 interview: “Women spend months agonizing over whether to try HRT. I tell them: try it. If it helps, you will know in two weeks. If it doesn’t, stop. There is no permanent commitment here. The failed trial of therapy while carefully monitoring symptoms is a legitimate medical strategy. You are not locking yourself into a decision for life.” The complete guide to menopause treatment options includes a one-page decision flowchart that you can bring to your next appointment — fill in your symptom score and health history, and the decision framework becomes visible in under five minutes.